



*[Handwritten signature]*

PATENT  
ATTORNEY DOCKET No: 58777.000012

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application Number : 10/642,272 Confirmation No.: 3248  
Applicant : Fumiyuki HATTORI, et al.  
Filed : August 18, 2003  
Title : THERAPEUTIC METHODS AND AGENTS FOR DISEASES  
ASSOCIATED WITH DECREASED EXPRESSION OF AOP-1  
GENE OR AOP-1  
TC/Art Unit : 1632  
Examiner: : Marcia Stephens NOBLE, Ph.D.  
Docket No. : 58777.000012  
Customer No. : 21967

**MAIL STOP AMENDMENT**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RE-SUBMISSION OF INFORMATION DISCLOSURE STATEMENT ITEMS**

Sir:

The Office Action of August 9, 2006 ("Office Action") stated that WO 95/04041, submitted in the Information Disclosure Statement filed December 4, 2003, was not considered because it is in a language other than English. Applicants provide herein resubmit WO 95/04041 and Tatewaki (1992), both of which have English language abstracts. Further, Tatewaki (1992) and Tatewaki (1995), respectively, were not considered because copies were not supplied. Applicants provide herein copies of Tatewaki (1992) and Tatewaki (1995).

Applicant provides herewith a PTO/SB/08A form listing WO 95/04041, Tatewaki (1992), and Tatewaki (1995). Consideration of the foregoing plus the return of a copy of the enclosed Form PTO/SB/08A with the Examiner's initials in the left column in accordance with MPEP § 609 is respectfully requested.

**CONCLUSION**

Applicants respectfully submit that claims are in condition for allowance, and such disposition is earnestly solicited. Should the Examiner believe that any issues remain after consideration of this Response, the Examiner is invited to contact the Applicants' undersigned representative to discuss and resolve such issues.

Applicants believe that no fees are required for entry of this Submission. However, in the event that any fees are deemed necessary by the U.S. Patent and Trademark Office to enter and consider this Submission or to maintain the present application pending, please charge the fees to the undersigned's **Deposit Account No. 50-0206**.

Respectfully submitted,

HUNTON & WILLIAMS, LLP

Dated: \_\_\_\_\_

3/14/07

By: \_\_\_\_\_



Robert M. Schulman  
Registration No. 31,196

Christopher J. Nichols, Ph.D.  
Registration No. 55,984

HUNTON & WILLIAMS LLP  
Intellectual Property Department  
1900 K Street, N.W. Suite 1200  
Washington, DC 20006-1109  
(202) 955-1500 (telephone)  
(202) 778-2201 (facsimile)

RMS/CJN:cdh



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT***(use as many sheets as necessary)*

<b>Application Number</b>	<b>10/642,272</b>
<b>Filing Date</b>	<b>August 18, 2003</b>
<b>First Named Inventor</b>	<b>Fumiyuki HATTORI</b>
<b>Art Unit</b>	<b>1632</b>
<b>Examiner Name</b>	<b>Marcia Stephens NOBLE, Ph.D.</b>
<b>Attorney Docket Number</b>	<b>58777.000012</b>

<b>Sheet</b>	<b>1</b>	<b>of</b>	<b>1</b>
--------------	----------	-----------	----------

**FOREIGN PATENT DOCUMENTS**

*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code:	Number - Kind Code (if known)				YES	NO
	1.	WO	95/04041 A1	02-09-1995	Taisho Pharmaceutical		<input type="checkbox"/>	<input type="checkbox"/>

**NON-PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	2.	TATEWAKI, Masuo, "Ketsueki Kansaibo no Zoshoku to Bunka", <i>Chem. Abstr.</i> (1992), Vol. 117, (Columbus, OH)		
	3.	TATEWAKI, Masuo, "Sekkekkyu Bunka no Yudo", <i>Chem. Abstr.</i> (1995), Vol. 122, (Columbus, OH)		

EXAMINER SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.